Risk markers of arterial aging in older adults — Paris Prospective III-2
Official title: Risk Markers of Arterial Aging and Subsequent Risk of Cardiovascular Diseases and Beyond. The Paris Prospective Study III-2
Run by Institut National de la Santé Et de la Recherche Médicale, France · NCT06079424 · Data updated 2026-11-12
This follow-up will re-examine people who took part in the original Paris cohort to measure changes in arterial stiffness and baroreflex over about 12–16 years and see if those changes predict later heart and blood vessel disease.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 60 Years to 95 Years |
| Sex | All |
| Enrollment | 7500 (estimated) |
| Sponsor | Institut National de la Santé Et de la Recherche Médicale, France Government |
| Locations | 1 site (Paris) |
| Status | Recruiting |
| Started | June 20, 2025 |
| Main results expected | May 2031 |
| Study ends | December 2033 |
| Registry record updated | September 17, 2026 |
| Trial ID | NCT06079424 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are original PPS3 participants who are alive, able to attend the Paris follow-up visit, and who sign the informed consent for PPS3-2.
✕Probably not a fit
People who are institutionalized or under legal guardianship or cannot attend the follow-up visit are excluded and would not be able to participate or benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The project re-invites survivors and original participants from the Paris Prospective Study III for a second physical exam roughly 12–16 years after baseline to describe the dynamics of vascular aging and baroreflex sensitivity. Participants will undergo high-precision carotid echo-tracking and a new ultrafast radial artery echo to measure arterial aging parameters in large and medium-sized arteries. Blood samples may be collected and biobanked depending on funding. The study will link changes in these vascular measures to subsequent cardiovascular disease events in the well-characterized cohort of 10,157 adults who were 50–75 years old at baseline.
Why it matters
Potential benefit: If successful, the study could identify early vascular aging markers that help predict and prevent future cardiovascular disease.
How similar studies have gone: Previous cohort research has linked arterial stiffness to cardiovascular risk, but long-term repeated measures using high-precision carotid echo-tracking and ultrafast radial echo over a 12–16 year interval are relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Being enrolled in PPS3 and having signed an informed consent for PPS3-2 Exclusion Criteria: * Institutionalized participants * Participants under guardianship * Participants under judicial safeguard measure
Where it's running
-
Centre d'Investigation Précliniques
Paris, France Recruiting
Study contacts
- Principal investigator: Jean-Philippe Empana, MD, PhD — Institut National de la Santé Et de la Recherche Médicale, France
- Study coordinator: Jean-Philippe Empana, MD, PhD
- Email: jean-philippe.empana@inserm.fr
- Phone: 33153988020
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Sleep and arterial function in hypertensive patients with poor sleep quality
This trial tests whether using cognitive-behavioural therapy for insomnia can improve artery health and well-being in adults with high blood pressure and poor sleep.
-
Can mouth health and chewing help explain arterial stiffness in healthy adults
This study tests whether a profile of oral health and function adds information about central arterial stiffness beyond traditional risk factors in healthy adults.
-
How Lipoprotein(a) affects artery stiffness, blood vessel lining, and heart muscle movement
This project will see if higher Lipoprotein(a) levels are linked to stiffer arteries, worse endothelial function, and changes in left atrial and left ventricular motion in adults 18–75.
-
Dapagliflozin to prevent chemotherapy-related heart damage in breast cancer
We will test if taking dapagliflozin 10 mg daily prevents heart and blood-vessel damage in adult women receiving anthracycline chemotherapy for breast cancer.
-
Upper-arm aerobic exercise for arterial stiffness in women treated for breast cancer.
This trial will test whether an upper-extremity aerobic exercise program can reduce arterial stiffness in women aged 40–69 who are at least 15 months after breast cancer surgery and are currently physically inactive.
-
Contactless vibrometer pulse‑wave test for heart and artery health
This pilot will try a contactless laser‑Doppler vibrometry and microwave radar device (Cardio P4) in people aged 58–72 to see if it can detect arterial stiffness and signs of coronary artery disease, aortic stenosis, or heart failure.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.